Vedolizumab for Crohn's disease

Bibliography

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361(21):2066-78
   PubMed Web of Science ®Google Scholar
• Hovde O, Moum BA. Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol 2012;18(15):1723-31
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17
   PubMed Web of Science ®Google Scholar
• Danese S. Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: ‘brothers in arms’. Gut 2011;60(7):998-1008
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365(18):1713-25
   PubMed Web of Science ®Google Scholar
• Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002;97(4):803-23
   PubMed Web of Science ®Google Scholar
• Cottone M, Renna S, Orlando A, Mocciaro F. Medical management of Crohn's disease. Expert Opin Pharmacother 2011;12(16):2505-25
   PubMed Web of Science ®Google Scholar
• Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002;31(1):147-66
   PubMed Web of Science ®Google Scholar
• Shen B. Managing medical complications and recurrence after surgery for Crohn's disease. Curr Gastroenterol Rep 2008;10(6):606-11
   PubMedGoogle Scholar
• Soler D, Chapman T, Yang LL, The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330(3):864-75
   PubMed Web of Science ®Google Scholar
• Desilva S, Kaplan G, Panaccione R. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Rev Gastroenterol Disord 2008;8(2):109-16
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panaccione R, Sandborn WJ, Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135(5):1493-9
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):590-9; quiz 600
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86(2):249-66
   PubMed Web of Science ®Google Scholar
• Mowat C, Cole A, Windsor A, Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60(5):571-607
   PubMed Web of Science ®Google Scholar
• Sans M, Lopez-San Roman A, Esteve M, Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology 2011;140(5 Suppl 1):S-109
   Google Scholar
• Cosnes J, Bourrier A, Bouhnik Y, Accelerated step-care therapy with early azathioprine (AZA) vs. conventional step-care therapy in Crohn's disease. A randomized study. Gastroenterology 2012;142(5 Suppl 1):S-161
   Google Scholar
• Feagan BG, Rochon J, Fedorak RN, Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332(5):292-7
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342(22):1627-32
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Panes J, Colombel JF, Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32(3):384-93
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128(4):862-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ, The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126(1):19-31
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4(5):621-30
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83
   PubMed Web of Science ®Google Scholar
• van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 2002;8(4):291-300
   PubMed Web of Science ®Google Scholar
• Cohen RD. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep 2002;4(6):497-505
   PubMedGoogle Scholar
• Kucharzik T, Maaser C, Lugering A, Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006;12(11):1068-83
   PubMed Web of Science ®Google Scholar
• Ogilvie AL, Luftl M, Antoni C, Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha. Int J Immunopathol Pharmacol 2006;19(2):271-8
   PubMed Web of Science ®Google Scholar
• Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Ther Adv Gastroenterol 2010;3(4):239-58
   PubMedGoogle Scholar
• Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010;33(11):969-83
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24):2499-507
   PubMed Web of Science ®Google Scholar
• Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 1993;150(8 Pt 1):3459-70
   PubMed Web of Science ®Google Scholar
• Vermeire S, Ghosh S, Panes J, The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60(8):1068-75
   PubMed Web of Science ®Google Scholar
• ClinicaTrials.gov. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01164904 [Cited 31 October 2012]
   Google Scholar
• Van Assche G, D'Haens G, Noman M, Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125(4):1025-31
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Malchow H, Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120(6):1339-46
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Chey WY, Wedel MK, A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5(2):215-20
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Barish C, Goff J, Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002;16(10):1761-70
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114(6):1133-42
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Chey WY, Goff J, Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51(1):30-6
   PubMed Web of Science ®Google Scholar
• Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012;20(1):1-18
   PubMedGoogle Scholar
• Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010;13(7):472-781
   PubMed Web of Science ®Google Scholar
• ChemoCentryx. CCR9 Program. 2012. Available from: http://www.chemocentryx.com/product/CCR9.html; Cited 2012 1/7/2012;18(8):1470-9
   Google Scholar
• Receptos. SPHINGOSINE-1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS. 2012. Available from: http://www.receptos.com/clinical-pipeline-at-receptos.php [Cited 29 October 2012]
   Google Scholar
• Parikh A, Leach T, Wyant T, Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2011
   PubMedGoogle Scholar
• Feagan BG, McDonald J, Greenberg G, An ascending dose trial of humanized A4B7 antibody in ulcerative colitis. Gastroenterology 2000;118(4 suppl 2):A874
   Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6(12):1370-7
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts PJ, Sands BE, Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. Gastroenterology 2012;142(5 Suppl 1):S145-6
   Google Scholar
• ClinicaTrials.gov. Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (GEMINI II). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00783692?term=gemini&rank=6 [Cited 3 November 2012]
   Google Scholar
• ClinicaTrials.gov. An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease (GEMINI LTS). 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00790933?term=C13008&rank=1 [Cited 30 November 2012]
   Google Scholar
• Ghosh S, Goldin E, Gordon FH, Natalizumab for active Crohn's disease. N Engl J Med 2003;348(1):24-32
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348(1):15-23
   PubMed Web of Science ®Google Scholar
• Leclerc M, Lesesve JF, Gaillard B, Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab. Leuk Lymphoma 2011;52(5):910-12
   PubMed Web of Science ®Google Scholar
• Rossi S, Motta C, Studer V, A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult Scler 2012;19(1):59-68
   PubMed Web of Science ®Google Scholar
• Parikh A, Fedyk E, Soler D, (Millennium: The Takeda Oncology Co. C, MA, US). Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrin. CCF. Florida. Inflamm Bowel Dis 2008;14:S18 P-0025
   PubMed Web of Science ®Google Scholar
• Milch C, Wyant T, Xu J, Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers. ECCO Inflamm Bowel Dis 2011;60:A407
   Google Scholar
• FDA. New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab). 2012. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm
   Google Scholar
• Fedyk ER, Wyant T, Yang LL, Exclusive antagonism of the alpha(4) beta(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012;18(11):2107-19
   PubMed Web of Science ®Google Scholar